Trevena (TRVN) Competitors

Trevena (NASDAQ:TRVN) and Oragenics (NYSE:OGEN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

Which has better earnings and valuation, TRVN or OGEN?

Oragenics has lower revenue, but higher earnings than Trevena. Oragenics is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevena	$443K	2.50	-$40.29M	-$47.04	-0.03
Oragenics	$40K	105.76	-$20.66M	-$1.70	-0.12

Is TRVN or OGEN more profitable?

Trevena's return on equity of 0.00% beat Oragenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevena	N/A	N/A	-119.55%
Oragenics	N/A	-2,087.95%	-486.56%

Does the MarketBeat Community favor TRVN or OGEN?

Trevena received 616 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 68.44% of users gave Trevena an outperform vote while only 0.00% of users gave Oragenics an outperform vote.

Company	Underperform	Outperform
Trevena	Outperform Votes 616 68.44%	Underperform Votes 284 31.56%
Oragenics	Outperform Votes No Votes	Underperform Votes 53 100.00%

Do analysts rate TRVN or OGEN?

Trevena currently has a consensus price target of $5.00, suggesting a potential upside of 290.63%. Given Trevena's stronger consensus rating and higher probable upside, equities analysts plainly believe Trevena is more favorable than Oragenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevena	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oragenics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Do insiders and institutionals hold more shares of TRVN or OGEN?

13.6% of Trevena shares are owned by institutional investors. Comparatively, 18.7% of Oragenics shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Comparatively, 10.1% of Oragenics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has more volatility & risk, TRVN or OGEN?

Trevena has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Oragenics has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.

Does the media refer more to TRVN or OGEN?

In the previous week, Trevena and Trevena both had 1 articles in the media. Trevena's average media sentiment score of 0.00 equaled Oragenics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevena	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oragenics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Trevena beats Oragenics on 9 of the 14 factors compared between the two stocks.